血清CCL11水平与T2DM合并冠状动脉粥样硬化性心脏病的相关性

doi:10.3760/cma.j.issn.1007-1245.2024.20.011

摘要/Abstract

摘要：

目的　探讨血清CC趋化因子配体11（CCL11）水平与2型糖尿病（T2DM）合并冠状动脉粥样硬化性心脏病（CAD）的相关性。方法　选取2022年1月至2024年4月商洛市中心医院收治的T2DM患者146例，按照是否合并CAD分为合并CAD组（CAD组）70例及单纯T2DM组（T2DM组）76例。CAD组中男43例，女27例，年龄（61.53±8.24）岁；T2DM组中男42例，女34例，年龄（59.30±6.86）岁。收集两组一般临床资料，检测血清CCL11水平及相关代谢指标。采用t检验、χ²检验。结果　CAD组T2DM病程长于T2DM组［（7.41±3.12）年比（6.08±2.58）年］，低密度脂蛋白胆固醇（LDL-C）和血清CCL11水平均高于T2DM组［（3.06±1.01）mmol/L比（2.60±0.78）mmol/L、（65.53±21.28）ng/L比（46.47±18.36）ng/L］，差异均有统计学意义（t=2.815、3.094、5.807，均P<0.05）。二元logistic回归分析结果显示，T2DM病程长、高LDL-C和血清CCL11水平均是T2DM合并CAD的危险因素（均P<0.05）。受试者操作特征曲线（ROC）分析显示，血清CCL11水平诊断T2DM合并CAD的曲线下面积（AUC）为0.751，灵敏度为65.7%，特异度为78.9%，约登指数为0.446。结论　T2DM病程长、高LDL-C和血清CCL11水平均是T2DM合并CAD的独立危险因素；血清CCL11水平对预测T2DM合并CAD具有较好的诊断价值。

关键词:

2型糖尿病, 冠状动脉粥样硬化性心脏病, CCL11, 相关性, 危险因素

Abstract:

Objective　To investigate the correlation between serum CC chemokine ligand 11 (CCL11) level and type 2 diabetes mellitus (T2DM) complicated with coronary atherosclerotic heart disease (CAD). Methods　A total of 146 T2DM patients admitted to Shangluo Central Hospital from January 2022 to April 2024 were selected and were divided into a CAD group (70 patients) and a T2DM group (76 patients) according to whether they were complicated with CAD or not. In the CAD group, there were 43 males and 27 females, aged (61.53±8.24) years. In the T2DM group, there were 42 males and 34 females, aged (59.30±6.86) years. The general clinical data of the two groups were collected, and the serum CCL11 level and related metabolic indicators were detected. t test and χ² test were used. Results　The duration of diabetes in the CAD group was longer than that in the T2DM group [(7.41±3.12) years vs. (6.08±2.58) years], and the levels of low density lipoprotein cholesterol (LDL-C) and serum CCL11 were higher than those in the T2DM group [(3.06±1.01) mmol/L vs. (2.60±0.78) mmol/L, (65.53±21.28) ng/L vs. (46.47±18.36) ng/L], with statistically significant differences (t=2.815, 3.094, and 5.807, all P<0.05). Binary logistic regression analysis showed that long duration of diabetes, high LDL-C and serum CCL11 levels were risk factors for CAD in T2DM patients (all P<0.05). The receiver operator characteristic curve (ROC) analysis showed that the area under the curve (AUC) of serum CCL11 level for diagnosing T2DM with CAD was 0.751, the sensitivity was 65.7%, the specificity was 78.9%, and the Youden index was 0.446. Conclusions　Long duration of diabetes, high LDL-C and serum CCL11 levels are independent risk factors for T2DM complicated with CAD. Serum CCL11 level has good diagnostic value in predicting T2DM complicated with CAD.

Key words:

Type 2 diabetes mellitus, Coronary atherosclerotic heart disease, CCL11, Correlation, Risk factors

王晨鸽李艳萍.

血清CCL11水平与T2DM合并冠状动脉粥样硬化性心脏病的相关性 [J]. 国际医药卫生导报, 2024, 30(20): 3402-3406.

Wang Chenge, Li Yanping.

Correlation between serum CCL11 level and T2DM complicated with coronary atherosclerotic heart disease [J]. International Medicine and Health Guidance News, 2024, 30(20): 3402-3406.

参考文献

[1] 谭琼琼,杨丽,朱玲棣,等. 个体化减重干预对肥胖合并T2DM患者体质量指数、糖脂代谢的影响[J]. 中国现代医学杂志,2022,32(9):84-90. DOI:10.3969/j.issn.1005- 8982.2022.09.014.
[2] Forray AI, Coman MA, Simonescu-Colan R, et al. The global burden of type 2 diabetes attributable to dietary risks: insights from the global burden of disease study 2019[J]. Nutrients, 2023,15(21):4613. DOI: 10.3390/nu15214613.
[3] 乔燕燕,贾黾泽. 高龄老年男性2型糖尿病合并冠状动脉粥样硬化性心脏病患者的临床特征及危险因素[J]. 生命科学仪器,2023,21(z1):55. DOI:10.11967/202300648.
[4] 李敏,李辉,刘艳,等. 2型糖尿病患者血清甘丙肽及瘦素与冠状动脉粥样硬化性心脏病的相关性研究[J]. 中国糖尿病杂志,2022,30(12):887-891. DOI:10.3969/j.issn.1006- 6187.2022.12.002.
[5] 杨菊,陈楠. 内脏脂肪面积/腿部肌肉质量与老年2型糖尿病并发冠状动脉粥样硬化性心脏病的关系[J]. 山东医药,2023,63(26):49-51. DOI:10.3969/j.issn.1002- 266X.2023.26.011.
[6] 张玲仙,李敏,李辉,等. 2型糖尿病病人血清可溶性ST2与冠状动脉粥样硬化性心脏病的相关性研究[J]. 蚌埠医学院学报,2023,48(12):1640-1644. DOI:10.13898/j.cnki.issn.1000-2200.2023.12.004.
[7] 方向南,柯瑞琼,洪世华,等. 血清去磷酸化未羧化基质gla蛋白水平与2型糖尿病合并冠状动脉粥样硬化性心脏病的相关性研究[J]. 中国糖尿病杂志,2021,29(3):168-172. DOI:10.3969/j.issn.1006-6187.2021.03.002.
[8] 侯晨晨,刘丹,卢青. 冠状动脉粥样硬化性心脏病合并2型糖尿病患者认知功能改变及影响因素分析[J]. 联勤军事医学,2023,37(4):354-359. DOI:10.13730/j.issn.2097-2148. 2023.04.017.
[9] 李莹,师体军,杨梦皎,等. 血清趋化因子与PMOP患者炎症和骨代谢指标的相关性及其诊断价值[J]. 广东医学,2023,44(4):488-493. DOI:10.13820/j.cnki.gdyx.20223040.
[10] 朱艳,单连美,张彩凤. 血清IL-1β、TNF-α、Ⅰ-FABP、CCL11在溃疡性结肠炎中的表达及其与病情严重程度间的关系[J]. 临床和实验医学杂志,2023,22(20):2172-2175. DOI:10.3969/j.issn.1671-4695.2023.20.012.
[11] Zajkowska M, Mroczko B. From allergy to cancer-clinical usefulness of eotaxins[J]. cancers (basel), 2021, 13(1):128. DOI: 10.3390/cancers13010128.
[12] Lavandoski P, Pierdoná V, Maurmann RM, et al. Eotaxin-1/CCL11 promotes cellular senescence in human-derived fibroblasts through pro-oxidant and pro-inflammatory pathways[J]. Front Immunol, 2023, 14:1243537. DOI: 10.3389/fimmu.2023.1243537.
[13] WH0. Definition, diagnosis and classification of diabetes mellitus and its complications, report of a WHO consultation. part 1: diagnosis and clas.sification of diabetes mellitus[M]. Geneva: World Health Organization, 1999: 3-7.
[14] Khanal MK, Bhandari P, Dhungana RR, et al. Poor glycemic control, cardiovascular disease risk factors and their clustering among patients with type 2 diabetes mellitus: a cross-sectional study from Nepal[J]. PLoS One, 2022, 17(7):e0271888. DOI: 10.1371/journal.pone.0271888.
[15] Jung CH, Mok JO. Recent updates on vascular complications in patients with type 2 diabetes mellitus[J]. Endocrinol Metab (Seoul), 2020, 35(2):260-271. DOI: 10.3803/EnM.2020.35.2.260.
[16] Medina-Leyte DJ, Zepeda-García O, Domínguez-Pérez M, et al. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches[J]. Int J Mol Sci, 2021, 22(8):3850. DOI: 10.3390/ijms22083850.
[17] Zhang P, Liang T, Wang X, et al. Serum-derived exosomes from patients with coronary artery disease induce endothelial injury and inflammation in human umbilical vein endothelial cells[J]. Int Heart J, 2021, 62(2):396-406. DOI: 10.1536/ihj.20-641.
[18] Xu S, Ilyas I, Little PJ, et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies[J]. Pharmacol Rev, 2021, 73(3):924-967. DOI: 10.1124/pharmrev.120. 000096.
[19] Mackman N. Eosinophils, atherosclerosis, and thrombosis[J]. Blood, 2019, 134(21):1781-1782. DOI: 10.1182/blood.2019003027.
[20] Onal B, Alaylioglu M, Yenmis G, et al. Pleiotropic effects of pitavastatin: a pilot study using the saphenous vein endothelial cell model of endothelial injury and prevention of atherosclerosis[J]. Eur Rev Med Pharmacol Sci, 2022, 26(14):5210-5217. DOI: 10.26355/eurrev_202207_29310.
[21] Rivera P, Martos-Moreno GÁ, Barrios V, et al. A combination of circulating chemokines as biomarkers of obesity-induced insulin resistance at puberty[J]. Pediatr Obes, 2021, 16(2):e12711. DOI: 10.1111/ijpo.12711.
[22] Perumalsamy S, Huri HZ, Abdullah BM, et al. Genetic markers of insulin resistance and atherosclerosis in type 2 diabetes mellitus patients with coronary artery disease[J]. Metabolites, 2023, 13(3):427. DOI: 10.3390/metabo13030427.
[23] Emamalipour M, Seidi K, Jahanban-Esfahlan A, et al. Implications of resistin in type 2 diabetes mellitus and coronary artery disease: Impairing insulin function and inducing pro-inflammatory cytokines[J]. J Cell Physiol, 2019, 234(12):21758-21769. DOI: 10.1002/jcp.28913.
[24] Venuraju S, Jeevarethinam A, Mehta VS, et al. Predicting severity of coronary artery disease in patients with diabetes using endothelial function measured with peripheral arterial tonometry: PROCEED study[J]. Angiology, 2019, 70(7):613-620. DOI: 10.1177/0003319719833265.
[25] Salvatore T, Pafundi PC, Galiero R, et al. Can metformin exert as an active drug on endothelial dysfunction in diabetic subjects? [J]. Biomedicines, 2020, 9(1):3. DOI: 10.3390/biomedicines9010003.
[26] Hamo CE, Echouffo-Tcheugui JB, Zhang S, et al. Diabetes duration and subclinical myocardial injury: the atherosclerosis risk in communities study (ARIC) [J]. Clin Chem, 2022, 68(10):1272-1280. DOI: 10.1093/clinchem/hvac117.
[27] Sanchez M, Potier L, Venteclef N, et al. 323-OR: Associations of leukocyte telomere length and related allelic variations with the risk of coronary events in people with long-standing type 1 diabetes[J]. Diabetes, 2022, 71 Suppl 1. DOI:10.2337/db22-323-or.
[28] Venuraju SM, Lahiri A, Jeevarethinam A, et al. Duration of type 2 diabetes mellitus and systolic blood pressure as determinants of severity of coronary stenosis and adverse events in an asymptomatic diabetic population: PROCEED study[J]. Cardiovasc Diabetol,2019, 18(1):51. DOI: 10.1186/s12933-019-0855-8.
[29] Lee J, Yun JS, Ko SH. Advanced glycation end products and their effect on vascular complications in type 2 diabetes mellitus[J]. Nutrients,2022, 14(15):3086. DOI: 10.3390/nu14153086.
[30] Mengstie MA, Chekol Abebe E, Behaile Teklemariam A, et al. Endogenous advanced glycation end products in the pathogenesis of chronic diabetic complications[J]. Front Mol Biosci, 2022, 9:1002710. DOI: 10.3389/fmolb.2022.1002710.
[31] Ruiz HH, Ramasamy R, Schmidt AM. Advanced glycation end products: building on the concept of the "common soil" in metabolic disease[J]. Endocrinology, 2020, 161(1):bqz006. DOI: 10.1210/endocr/bqz006.